Tower Research Capital LLC TRC Boosts Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Tower Research Capital LLC TRC grew its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 148.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,711 shares of the specialty pharmaceutical company’s stock after purchasing an additional 7,000 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Collegium Pharmaceutical were worth $336,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Invesco Ltd. boosted its stake in shares of Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company’s stock valued at $50,876,000 after purchasing an additional 289,335 shares during the period. Principal Financial Group Inc. lifted its stake in Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after acquiring an additional 64,958 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company’s stock worth $47,603,000 after acquiring an additional 5,480 shares during the last quarter. Royce & Associates LP lifted its stake in Collegium Pharmaceutical by 11.0% in the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company’s stock worth $9,728,000 after acquiring an additional 33,674 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after acquiring an additional 175,892 shares during the last quarter.

Collegium Pharmaceutical Stock Up 0.2 %

Shares of NASDAQ:COLL opened at $27.06 on Friday. The company has a market capitalization of $869.49 million, a PE ratio of 11.66 and a beta of 0.76. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The firm has a 50 day simple moving average of $28.21 and a 200-day simple moving average of $30.50.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, equities analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 19th. Piper Sandler decreased their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Insider Activity

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares of the company’s stock, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 2,255 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the transaction, the executive vice president now directly owns 124,421 shares in the company, valued at $3,732,630. This represents a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,693 shares of company stock valued at $2,334,994 in the last ninety days. 2.51% of the stock is currently owned by company insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.